What is Leerink Partnrs’ Forecast for BBIO Q1 Earnings?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a report released on Monday, February 24th. Leerink Partnrs analyst M. Foroohar anticipates that the company will post earnings per share of ($0.73) for the quarter. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s Q2 2025 earnings at ($0.85) EPS, FY2025 earnings at ($3.40) EPS, FY2026 earnings at ($1.79) EPS, FY2027 earnings at $0.40 EPS, FY2028 earnings at $3.10 EPS and FY2029 earnings at $4.85 EPS.

Several other equities analysts have also commented on BBIO. Citigroup increased their price objective on BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Evercore ISI increased their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research report on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $95.00 price objective on shares of BridgeBio Pharma in a research report on Friday, February 21st. Bank of America increased their price objective on BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, November 25th. Finally, HC Wainwright restated a “buy” rating and set a $49.00 price target on shares of BridgeBio Pharma in a research report on Thursday, February 13th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.67.

BridgeBio Pharma Trading Down 2.6 %

Shares of BridgeBio Pharma stock opened at $33.45 on Wednesday. The firm has a market capitalization of $6.36 billion, a PE ratio of -11.74 and a beta of 1.07. The business’s 50-day moving average price is $32.35 and its 200-day moving average price is $28.17. BridgeBio Pharma has a 12 month low of $21.62 and a 12 month high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The firm had revenue of $5.88 million during the quarter, compared to analysts’ expectations of $4.04 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of BridgeBio Pharma by 6.2% in the 4th quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company’s stock valued at $413,738,000 after purchasing an additional 879,059 shares during the period. Janus Henderson Group PLC lifted its stake in shares of BridgeBio Pharma by 1.9% in the 4th quarter. Janus Henderson Group PLC now owns 4,907,533 shares of the company’s stock valued at $134,672,000 after purchasing an additional 89,521 shares during the period. Farallon Capital Management LLC lifted its stake in shares of BridgeBio Pharma by 140.1% in the 4th quarter. Farallon Capital Management LLC now owns 4,195,000 shares of the company’s stock valued at $115,111,000 after purchasing an additional 2,448,000 shares during the period. Frazier Life Sciences Management L.P. lifted its stake in shares of BridgeBio Pharma by 1.1% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock valued at $104,285,000 after purchasing an additional 40,000 shares during the period. Finally, Capital Research Global Investors lifted its stake in shares of BridgeBio Pharma by 34.9% in the 4th quarter. Capital Research Global Investors now owns 3,526,747 shares of the company’s stock valued at $96,774,000 after purchasing an additional 912,439 shares during the period. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Insider Transactions at BridgeBio Pharma

In other news, CFO Brian C. Stephenson sold 4,148 shares of BridgeBio Pharma stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $36.16, for a total value of $149,991.68. Following the sale, the chief financial officer now directly owns 102,464 shares in the company, valued at approximately $3,705,098.24. This trade represents a 3.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Global Investors Lp Viking sold 3,065,616 shares of BridgeBio Pharma stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $34.90, for a total value of $106,989,998.40. Following the completion of the sale, the insider now owns 22,055,375 shares in the company, valued at approximately $769,732,587.50. This represents a 12.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,496,239 shares of company stock worth $122,612,036. 24.66% of the stock is currently owned by insiders.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.